FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: brca
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Study : Impact of breast cancer and BRCA mutations on fertility preservation
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People considering fertility preservation.
Timely family planning discussions are important for people diagnosed with breast cancer as well as those who have an inherited a BRCA1 or BRCA2 mutation. This study looked at the number of mature eggs recovered when ovaries were stimulated for fertility preservation or preimplantation genetic testing among three groups and found that the number of eggs collected was similar. (Posted 10/31/24)
Read MoreRelevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : More research points to the benefits of pancreatic cancer screening
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People undergoing pancreatic cancer screening
People with a family history of pancreatic cancer or those who have an inherited mutation that increases risk may benefit from yearly pancreatic cancer screening. Yearly screening may lead to early diagnosis and longer survival. (Posted 10/8/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Study : Skin cancer among women with an inherited BRCA mutation
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Most relevant for: People with an inherited BRCA mutation
Women with an inherited BRCA1 and BRCA2 mutation have an increased risk of various cancers. Study results suggest that although the risk of non-melanoma skin cancer in these women is similar to the risk of the general population, the risk of melanoma skin cancer is slightly increased. (Posted 7/25/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Yearly breast MRI screening improves outcomes for women with inherited BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with a BRCA1 or BRCA2 mutation who are considering breast MRI screening
An international research study of yearly breast MRI screening among women with BRCA1 and BRCA2 gene mutations found that BRCA1 carriers who had MRI screenings were less likely to die of breast cancer than those who did not. Additional studies with more BRCA2 mutation carriers are needed to determine if yearly breast MRIs reduce deaths from breast cancer in this group. (Posted 6/24/24)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Ovary removal reduces risk of death from any cause in people with BRCA mutations
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People who have had a risk reducing bilateral oophorectomy
People who test positive for an inherited BRCA1 or BRCA2 mutation can reduce their risk of ovarian cancer by having both ovaries and fallopian tubes removed. A study published in 2024 found an added benefit of this surgery – a lower risk of death from any cause by age 75. (Posted 5/23/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Genes linked to aggressive prostate cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People diagnosed with advanced prostate cancer
Previous research has linked some inherited mutations to prostate cancer risk. This study found a link to additional genes that should be added to prostate cancer gene panel tests. The study also looked at which genes were most closely linked to aggressive prostate cancer that is more likely to spread. (Posted 2/1/24)
Este artículo está disponible en español.
Read MoreUpdate : A breast cancer vaccine for people with an inherited BRCA1, BRCA2 or PALB2 mutation
Most relevant for: People at increased risk for breast cancer undergoing prophylactic bilateral mastectomy due to an inherited mutation in BRCA1, BRCA2 or PALB2. People with TNBC who still have breast cancer after chemotherapy.
A breast cancer vaccine is showing promise in early clinical trials. Initially, the vaccine was tested in people with triple-negative breast cancer (TNBC) who were at high risk for recurrence. Now the vaccine is being tested to lower breast cancer risk among people with an inherited mutation in BRCA1, BRCA2 or PALB2. It is also being tested in people with triple-negative breast cancer who are at high risk for recurrence and are taking the immunotherapy drug Keytruda (pembrolizumab) after completing chemotherapy. (Posted 1/31/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : H. pylori bacteria infection and risk of stomach cancer in mutation carriers
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People who are at increased risk for stomach cancer due to an inherited mutation.
The results of a study in Japan show that people with a bacterial infection called H. pylori and an inherited mutation in an ATM, BRCA1, BRCA2 or PALB2 gene have a high risk of stomach cancer. (Posted 1/19/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Benefit of pancreatic cancer screening
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with an inherited BRCA1 or BRCA2 mutation
Among people with an inherited mutation in a BRCA1 or BRCA2 gene, screening for pancreatic cancer found most cancers at an earlier stage when they could be treated by surgery. Posted 1/17/24)
Este artículo está disponible en español.
Read MoreUpdate : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
Read More